Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. - Wikidata - awgldk - TriplyDB

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

http://www.wikidata.org/entity/Q33564399

about

Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly Recent advances in the management of acromegaly Combined treatment of somatostatin analogues with pegvisomant in acromegaly The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly Diabetes in Patients With Acromegaly.Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis.Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery.Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Lanreotide autogel in acromegaly - a decade on.A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.Adverse events associated with somatostatin analogs in acromegaly.New therapeutic agents for acromegaly.Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.Current and future medical treatments for patients with acromegaly.The role of combination medical therapy in the treatment of acromegaly.Somatostatin receptor ligands in the treatment of acromegaly.Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response.Recent Progress in the Medical Therapy of Pituitary Tumors Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly.A paradigm shift in the medical treatment of acromegaly: from a 'trial and error' to a personalized therapeutic decision-making process.Novel Somatostatin Receptor Ligands Therapies for Acromegaly.How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature Updates in Diagnosis and Treatment of Acromegaly

P2860

Q26741026-03D9DC97-D7B6-4D62-B6A1-564AF07ABC9F Q26766199-1BE37484-CAF5-4FFB-AB52-0F1F860F2B76 Q26776366-736476EA-A054-4020-B267-17D34CE3E4DE Q26796357-09FEBA88-79AB-4931-AEF6-C6FBDEA71FF6 Q30238646-E385B619-3C1B-463E-A0F9-65BF2C4BC16B Q30353080-E0A3CC1C-20D0-4F7F-BB1E-1B3441A8888E Q31027960-F24480BC-3547-462E-B312-530BA27CBF10 Q31144045-62EB6533-858A-4F1A-82D3-739DE413FEF9 Q35981653-80856935-6082-4652-8BE2-7DCAD2C1D5D9 Q36270815-AA3B6DC7-AADE-4634-BB99-D60FC284C40F Q36704499-87B19EE3-D8A2-4164-90CB-F9CDFDDFCCE6 Q37428560-9C94F40C-20AA-4CF9-B091-0EE3DFEC870C Q37678328-9B96F1A9-117C-4692-A6E7-1418B722ECEF Q37726440-956F8E57-8E00-4E7A-8586-D8770D95DEE4 Q38231413-ECC1C084-2EE7-4DC5-A42C-2833A786A803 Q38246440-FEDA2B2C-6241-4FC0-8FE6-8FC6C85A5073 Q38259409-F56D2F2B-1CB4-4029-8D81-8444AF283881 Q38373377-A306234A-23CA-4E62-B06E-8344BF37879B Q38548973-A40F5A86-9A5E-49F8-BF76-AFA85385F66A Q38648739-260DC9CB-939B-49F3-AEBC-3707E53439DD Q38658730-0F509624-ED71-4FEB-BB38-5400ED53DA8F Q38847622-28E90C34-4D58-4274-8A7E-05B750295E51 Q38927318-1A5EC20E-19D5-4FFD-9CFB-81E3DC36910E Q39125449-FC7EE260-6949-4A45-ABA2-3834C2769386 Q39294965-BE036DA8-7D59-4367-B2F6-81810076199E Q39420116-C4C1DDD4-9869-416B-AC7D-5302C825FE25 Q39687911-4603CD9F-0750-4E4D-B97F-7313B38D321A Q41103332-BF1EAA68-02DF-45D7-8585-A4E5C0173351 Q45065721-49506A26-9C1B-410A-A046-3502AE7C0A3B Q50930330-9002A4E2-79B9-4FC2-83F9-23356B804314 Q52643700-F255B72C-9BDB-4FFF-B08C-3E21F4787F06 Q54939988-277891A0-F2CF-442E-AD37-F1D5895E65AE Q55293690-5C500A58-140E-4369-ACD3-CEEB2178C1C2 Q57144951-3ECB0DBB-A0AE-41B9-9A3C-76F19D18FF78 Q57822729-C36C2A45-7525-4D2F-BADE-68AE261CCB64

P2860

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

http://www.wikidata.org/entity/Q33564399

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@ast

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@en

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@nl

type

label

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@ast

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@en

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@nl

prefLabel

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@ast

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@en

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@nl

P1433

Q33564399-05164A3B-F6E8-4974-B1EF-D41BC85E8432

P1476

Q33564399-B142B037-FBE8-4880-A8E4-853A723B21BD

P2093

Q33564399-1B862ABC-F976-4067-8049-5157BEAFE533

Q33564399-21E5E192-FE16-4D82-BC4D-25BD7C3C1FAA

Q33564399-2DF23A17-9C12-450F-AC58-1DDFCA0C4B52

Q33564399-50029F60-7339-4CDB-BCA8-C0F253698ECB

Q33564399-545F26C3-493C-44D6-A11F-71F320E11923

Q33564399-6E27B722-2DAB-4476-BFE2-69EAC75E39B2

Q33564399-8A30C6B1-4532-48DA-B0D6-32F53B9C018A

Q33564399-943C8D07-07D4-4D87-93E4-E445A100DDCC

Q33564399-EE887E82-B9C2-493A-8ADA-10D954D54107

P2860

Q33564399-077FE6B2-A0C5-4275-8BF5-C3B14FFC6015

Q33564399-1EE02324-074D-4FDA-89A8-3AC2078DDAC8

Q33564399-267013A8-00D8-4468-8446-B9E665FDA831

Q33564399-3851AA9F-1E9F-4D56-B295-93B3B66EBAA7

Q33564399-4DA4FFFC-194C-451E-A5FC-FBD9DCF22C46

Q33564399-4FB3297B-0822-46AC-B724-75B57876E08A

Q33564399-535C3A1F-119D-4DFF-8A18-9A829F59EA9E

Q33564399-53AA3B29-1D32-4F86-9130-D965610200A4

Q33564399-56B01EE2-0F57-4E08-A9E2-4092AF83D2AA

Q33564399-619726C7-4D08-4193-8164-AD0F8AD803B4

P304

Q33564399-76048055-3AB2-4F3C-9E77-DA4F2158724A

P31

Q33564399-9141DA15-7229-4661-A3D0-FA16615A7773

P356

Q33564399-65A31057-E656-4DC2-8026-2AC4535946D9

P407

Q33564399-0E9BE279-ADB4-4A69-BB1A-30C6C845FDEA

P433

Q33564399-F049DF2C-69DB-4EDE-BE3E-0CB44F9E4F74

P478

Q33564399-EA2ED8CB-17C7-49EC-8DE1-431B41A559ED

P577

Q33564399-AA7750E8-11D5-4BA0-A637-665ACFAEB1C1

P698

Q33564399-1DF44429-4957-4CFB-89ED-E04E5CD26142

P921

Q33564399-5C2BD6D1-901D-4D7B-B884-5B6AFB242830

P932

Q33564399-3B9E7D08-BF60-4943-9F04-C08426AD16B9

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Tumor shrinkage with lanreotid ...... ve multicenter clinical trial.

@en

P2093

Antoine Clermont

http://www.w3.org/2001/XMLSchema#string

Antoine Tabarin

http://www.w3.org/2001/XMLSchema#string

Daniel Flanagan

http://www.w3.org/2001/XMLSchema#string

Gaëtan Prévost

http://www.w3.org/2001/XMLSchema#string

John S Bevan

http://www.w3.org/2001/XMLSchema#string

PRIMARYS Investigators

http://www.w3.org/2001/XMLSchema#string

Pascal Maisonobe

http://www.w3.org/2001/XMLSchema#string

Philippe J Caron

http://www.w3.org/2001/XMLSchema#string

Stephan Petersenn

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis on the effects of octreotide on tumor mass in acromegaly

Standards of medical care in diabetes--2013

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.

Guidelines for acromegaly management: an update.

P304

1282-1290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2013-3318

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24423301

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4009579

http://www.w3.org/2001/XMLSchema#string